Biologics License Application submitted to FDA for efbemalenograstim alfa (Ryzneuta) for chemotherapy-induced neutropenia

Phase III trial of this recombinant fusion protein containing G-CSF at the amino terminal and human IgG2-Fc fragment at the carboxyl terminal comparing its efficacy and safety vs. pegfilgrastim met its primary and secondary endpoints.

Source:

Biospace Inc.